Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and
antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir)
administered as two-day monotherapy followed by ABT-267 in combination therapy with other
direct-acting antiviral agents (DAAs) ABT-450 with ritonavir (ABT-450/r) and ABT-333 (also
known as dasabuvir) plus ribavirin (RBV) in patients with chronic Hepatitis C virus (HCV)
infection without cirrhosis.